How Reverse Plagiarism Enabled the Theranos Fraud

By now, pretty much everyone knows the story of Theranos, the med-tech startup founded by Elizabeth Holmes that famously imploded in 2016 in a cloud of scandal and fraud.
As of this writing, both Holmes and her co-founder Ramesh Balwani are serving out prison sentences related to their actions at the company. That company promised to revolutionize medical testing, but only offered false promises and a lot of dubious diagnostics.
But before things flamed out, at the peak of the company’s success, it was valued at $9 billion and had scored major partnerships with Walgreens and Safeway. Over the five years the company was in operation, it had raised more than $400 million in funding.
How such a clear fraud could have achieved this is still a subject of debate. However, one element that didn’t receive much attention at the time was that the company boosted its credibility on the back of others.
Through the aid of a little “reverse plagiarism,” Theranos was able to convince investors, regulators, and the public that it was capable of delivering on its promises, even though it was purely smoke and mirrors.
Fake it Till You Make It
One of the biggest successes of Theranos was its September 2013 deal with Walgreens. That deal was a major coup for the company, as Walgreens announced it would be offering Theranos’s blood-testing tests in its stores.
This was a big deal not only because it attracted investors, but also because it was the major coming out party for Theranos as a company.
But, knowing what we know now, it’s surprising that Theranos was able to convince Walgreens that it was capable of delivering on its promises. In 2021, during Holmes’ trial, we learned one of the tricks that Theranos used to build its credibility.
Theranos, as part of its pitch to Walgreens, had submitted two reports, one bearing a Pfizer logo and the other featuring the logo of Schering-Plough, another large pharmaceutical company. In neither case had the company whose logo appeared approved the statements.
The Schering-Plough was particularly egregious. The report had originally been submitted to Schering-Plough itself as the company was evaluating Theranos’ products. However, when Holmes sent the report to Walgreens, she added the Schering-Plough logo to the report and tweaked the language to make it appear more decisive.
While it’s unlikely those reports were the only thing that convinced Walgreens, they were a big part in Theranos getting the deal. That, in turn, helped the company raise more money and build its reputation as a revolutionary company in the medical field.
Fraud on Many Levels
Obviously, with a company like Theranos, it’s hard to claim that breaching authorship was the worst thing the company did. The company committed fraud upon fraud, and much of it was on unsuspecting patients whose health was at stake.
So while reverse plagiarism is just one fraud on the pile, it ultimately was a lynchpin for the whole scheme.
If Theranos had been honest about who drafted the reports, I doubt that Walgreens would have taken them seriously. A self-written report from a startup has much less weight than a similar report from a major pharmaceutical company.
Would Walgreens have signed that deal if they knew who wrote the reports? It’s impossible to say. But it definitely would have been less likely, especially without more information.
To be clear, Walgreens has some culpability in this. Given the importance of the deal and that it could impact the health of its customers, Walgreens could have and should have done more due diligence. Simply reaching out to Schering-Plough and Pfizer to verify the reports could have gone a long way to stopping the fraud.
Holmes, who admitted to putting the logos on the reports, said she did so because she wanted to make it clear that the work was done in conjunction with the two companies. At trial, she said she didn’t intend to deceive anyone but regretted doing so.
But that argument falls flat. Not only did she commit so many other frauds as part of the Theranos scheme, but there really isn’t another reasonable interpretation of what those logos were supposed to mean.
Putting a name or logo on a report is, in and of itself, an endorsement of that report’s content. Especially when they are due diligence reports meant to show the efficacy of a product.
So while this might not be Theranos’ biggest deception, it was definitely one of its more important ones.
Bottom Line
The story shows the power and importance of authorship. Authorship is not just a matter of giving credit where it’s due. Authorship contextualizes a work and is a major factor in determining how much weight and consideration a work gets.
Two reports claimed to be by major pharmaceutical companies earned Theranos a massive deal with a major retailer. That, in turn, helped them secure hundreds of millions of dollars in funding and raised their valuation to $9 billion.
Would being honest about authorship have made a difference? Maybe not. But it’s hard to imagine Walgreens being so eager to sign a deal with Theranos based on a pair of reports from their own staff. They would, rightly, want some third-party verification of the company’s claims.
Unfortunately, the issue of authorship is only going to become more difficult in the future. AI is already blurring the lines between human and machine authorship. Deepfakes and AI-generated content are already making it fake others saying things they didn’t. Knowing who said what is already a fundamental challenge and one that only getting more difficult.
This case, in particular, shows why that is important. It illustrates perfectly why lying about authorship isn’t about stealing credit, it’s about often stealing credibility.
That’s what Theranos stole. And they used that theft to get millions in funding and risk patents’ lives.
Want to Reuse or Republish this Content?
If you want to feature this article in your site, classroom or elsewhere, just let us know! We usually grant permission within 24 hours.
